N4 Pharma PLC AGM Statement (6811C)
June 19 2019 - 2:00AM
UK Regulatory
TIDMN4P
RNS Number : 6811C
N4 Pharma PLC
19 June 2019
19 June 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
AGM statement
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for vaccines and
cancer treatments, announces that at its annual general meeting,
being held later today, Nigel Theobald, Chief Executive Officer,
will provide the following update on the timings for the recently
announced repeat of the in vivo work at University of Queensland
("UQ").
As previously announced, studies to date have demonstrated that
Nuvec(R) consistently promotes transfection in in vitro experiments
using both DNA and messenger RNA (mRNA) plasmids. The primary in
vivo study conducted by UQ also demonstrated that Nuvec(R) is
effective in vivo, as a measurable antibody response was achieved
using Ovalbumin plasmid DNA (OVA pDNA).
Evaluation of subsequent in vivo studies conducted by other
laboratories indicated that the preparation and loading of Nuvec(R)
with DNA or mRNA differed to the methods used by UQ in the primary
study. By returning to UQ to repeat the successful in vivo work
using OVA pDNA, the Company expects to affirm the precise loading
protocol and methodology and to properly document the process for
successful technology transfer to other CROs and partners. This
will provide the benchmark conditions to be used to evaluate the
delivery of antigen by Nuvec(R) in a well characterised oncology
efficacy model.
The relevant committees at UQ have now approved the commencement
of the studies and, with this approval, the experiments are
expected to start on 21 June 2019. UQ has advised that results are
expected to be available in approximately two months. The repeat
work at UQ will be monitored and recorded by N4's Head of CMC
Programme Development, Dr Allan Hey.
The Board is pleased to now have greater clarity on the timing
of the next UQ work and believe a properly documented protocol, by
repeating the earlier successful study, will enable the Company to
accelerate other studies. The Company remains well funded to
achieve this objective.
The Directors of the Company are mindful that Nuvec(R) will not
work first time for every application and in every experiment.
There are many variables to consider in any pre-clinical
experiment, such as the antigen itself, how to load it onto
Nuvec(R), the dose, concentration of Nuvec(R) and injection volume
and understanding how these factors can cause inconsistency is an
important part of Nuvec(R)'s development. The Directors remain
confident that Nuvec(R) has the potential to be an innovative and
effective delivery system in the field of nucleic acid vaccines and
therapeutics."
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44 (0)203 328 5656
James Reeve/Asha Chotai
Scott PR
Georgia Smith Tel: +44 (0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMBCGDLGXBBGCI
(END) Dow Jones Newswires
June 19, 2019 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024